December 5, 2022

A UK study has found that the mRNA Covit-19 vaccine has the greatest booster impact

  • The data behind the UK booster decision has been released
  • Pfizer and Moderna provide large antibody, T-cell stimulants
  • Broad T-cell responses provide confidence in variance protection

London, December 3 (Reuters) – Pfizer-produced Covit-19 vaccines (PFE.N) And Moderna (MRNA.O) 10-12 weeks after the second dose, the use of MRNA technology provides the greatest stimulus for antibody levels, a new British study has found.

The “COV-Boost” study was quoted by British officials as saying they wanted to use Pfizer and Moderna in the country’s booster campaign, but the data is now publicly available. read more

The study found that six of the seven boosters tested enhanced immunity after the initial vaccination with the Pfizer-Bioentech vaccine, while seven of the seven boosters gave immunity after two doses of astrogen. (AZN.L) Vaccine.

Sign up now for unlimited free access to

“The third dose is effective for many of the vaccines and various combinations we have tested,” said Professor Saul Fast, an immunologist at the University of Southampton and a pioneer of the experiment.

In a study published late Thursday, Pfizer’s full dose or half dose or Moderna’s full dose gave strong impetus to both antibody and D – cell levels, although initially Pfizer or AstraZeneca.

“The four most widely used vaccines in the UK are essentially the same level of immunity, and they are equally effective,” said Professor Eleanor Riley, an immunologist at the University of Edinburgh. Policy change at booster intervals is also supported by data, he said.

“These data support the JCVI (Vaccine Group) decision earlier this week to bring booster doses 3 months ahead after the second vaccination.”

The study found that when AstraZeneca, Novavax, Johnson & Johnson and Curevac were given as boosters, they had slightly increased antibody levels for the initial vaccine. However, although Valneva increased antibodies in those initially vaccinated with AstraZeneca, it did not stimulate Pfizer.

Faust said the COV-Boost study dates back to the prevalence of the alarming Omicron variant, and shared samples with the UK Health Security Agency to generate data on Omicron.

However, the study found that booster shots helped to create a broader T-cell response against beta and delta types, which may play a key role in long-term protection.

A separate study by Imperial College London was published late Thursday on how early expression of SARS-CoV-2 shapes immune responses, as well as finding a good T-cell response to both alpha and delta after vaccination.

Sign up now for unlimited free access to

Report by Alistair Smout; Editing by Bernadette Bam and Mark Heinrich

Our standards: Thomson Reuters Trust Principles.